We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.00 | 12.00 | 17.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.76 | 58.35M |
TIDMREDX
RNS Number : 2212M
Redx Pharma plc
11 October 2016
11 October 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company")
Exercise of Options and Total Voting Rights
Redx, the drug development company, announces that it has received notice from employees of the Company to exercise share options over an aggregate of 145,319 ordinary shares of 1p each in the Company ("Ordinary Shares"). The exercise price is 50p for 110,025 Ordinary Shares and 42.5p for the remaining 35,294 Ordinary Shares.
Application has been made for the 145,319 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will commence on 17 October 2016. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission will be 93,697,957. Accordingly, the figure of 93,697,957 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Redx Pharma Plc Neil Murray, Chief Executive T: +44 151 706 4747 Karl Hård, Head of Investor T: +44 7491 Relations & 651 406 Corporate Communications Cantor Fitzgerald Europe (Nomad T: +44 20 & Broker) 7894 7000 Phil Davies/ Michael Reynolds KTZ Communications T: +44 20 3178 6378 Katie Tzouliadis/ Viktoria Langley/ Emma Pearson
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhea, bone tumours, skin, brain, breast, pancreatic and blood cancers.
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEGGGGWUUPQURG
(END) Dow Jones Newswires
October 11, 2016 04:32 ET (08:32 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions